I don’t disagree but I would say that timing has never been more important. All hands on deck for review and EUA submission. Lives literally on the line.
But, to your point don’t submit something that allows the FDA to delay approval because of some technicality
"CytoDyn completed enrollment of 390 patients in its Phase 2b/3 randomized clinical trial for the severe-to-critically ill COVID-19 population and expects to release results in mid-January 2021."
FWIW I wouldn't guess a specific date. IMO "shortly thereafter" the 28 days following full enrollment, and "mid-January" as estimates are fine by me.
IMO there may be quite a few new people desperately looking at the science of this company at the end of this month and beyond when hospitalizations are straining numerous systems.
Market Data 
Markets 
